Movers and SHAKERS
Ayala Pharmaceuticals (AYLA)
Noblecon17 Presentation Emphasizes the Positive Trajectory and the Upcoming Catalysts
Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company's current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell specific leukemia.
Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
CEO presentation highlighted the path forward for the company. Roni Mamluk, CEO of Ayala Pharmaceuticals participated in the Targeted Oncology Therapeutics panel and presented at Noblecon17. A replay can be accessed at https://www.channelchek.com/news-channel/NobleCon17_Rebroadcast . Both her participation and presentation highlighted Ayala’s foundation, pipeline, the roadmap to the next steps, and also value-generating catalysts for the shares.
Pipeline offers substantial value expansion. The company recently initiated Phase 2 in triple-negative breast cancer (TNBC) and received FDA’s approval to commence pivotal Phase 2/3 trial (RINGSIDE) in desmoid tumors (anticipated in H1 2021). We believe Springworks’ topline data from the registrational Phase 3 trial (DeFi) in Q2/Q3 2021 will act as a major inflection point for the company, as it ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.